Chongqing Lummy Pharmaceutical Hits Day High with 8.25% Surge

Chongqing Lummy Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 8.25% on March 6, 2026. The stock reached an intraday high of CNY 5.27, marking a notable achievement for the small-cap company within the pharmaceuticals and biotechnology sector. In terms of performance metrics, Chongqing Lummy has outperformed the China Shanghai Composite index, which saw a modest increase of 0.38% on the same day. Over the past week, the company's stock has risen by 3.35%, while its one-month performance stands at 4.17%. Impressively, the stock has delivered a 40.0% return over the past year, significantly surpassing the 21.98% gain of the broader index. Despite these positive short-term trends, the company faces challenges, including a low return on capital employed and a history of declining net sales. With a market capitalization of CNY 4,142 million, Chongqing Lummy continues to navigate a complex financial landscape as it seeks to stabilize its operations and improve its financial health.